My first buy was $0.34, next buy in was $0.31, than bought more at $0.45, and more again at $0.54, sold half of my new position at $0.795, and want to wait for the FDA news before I sell anymore, and just think that there is going to be a lot of interest by traders to buy in on every manipulated trick pull back by corrupt Wall Street to steal from the clueless, and it would take bad news for it to fall below $0.50 at this point,and there is a large amount of traders in the buy zone of the high $0.50s low $0.60s, that has bounced it many times already, and if there is real positive news, there will be NO mercy for bone heads playing games and caught naked short.
Good luck with that, trading desk are making comments that it's about to have a rip roaring bounce back above $0.70, that there is a on going plan to grab as many shares as possible by tricking the clueless to sell out to them right now, and their just about done stealing shares from the dumb money.
Over time with no news it should go back to at least a buck with all of the big money realizing this stock was way over pummeled in the past year, and it's a bargain down here with potential to having 300% profit from here, those who are excited about news that's past due all know that positive FDA news could more than triple this stock over night.
Only the most clueless people would be selling at these rock bottom basement prices.
Amedica Corporation Analyst Rating Update
by Stephanie Nicolas on June 9, 2015
Amedica Corporation (NASDAQ:AMDA): The Company shares has received a rating of Buy from 2 Wall Street Analysts. Amedica Corporation shares have received a Mean Price Target of $2. According to the rating issued from 2 Wall Street Analysts, the High Price Target is seen at $3 while the Lower end of the Price Target is seen at $1. The Median Price Target is calculated at $2.
Amedica Corporation (NASDAQ:AMDA) rose 1.06% or 0.0034 points on Monday and made its way into the gainers of the day. After trading began at $0.33 the stock was seen hitting $0.338 as a peak level and $0.315 as the lowest level. The stock ended up at $0.325. The daily volume was measured at 1,461,125 shares. The 52-week high of the share price is $5.16 and the 52-week low is $0.2035. The company has a market cap of $20 million. According to the SEC Form-4 filing, the Company has disclosed other insider buying and selling activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Amedica Corp, Truetzel David W. had sold 15,000 shares worth of $10,200 in a transaction dated December 11, 2014. In this transaction, 15,000 shares were sold at $0.68 per share.
Amedica Corporation (Amedica) is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. The Company market spinal fusion products and are developing products for use in total hip and knee joint replacements. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a complementary line of non-silicon nitride spinal fusion products which allows us to provide surgeons and hospitals with a broader range of products. These products include three lines of spinal fusion devices and five types of orthobiologics, which are used by surgeons to help promote bone growth and fusion in spinal fusion procedures.